Redeye comments on Oncopeptides Q4 report, whose topline has already been communicated.
Redeye provides its initial take on Surgical Science, with sales relatively in line with expectation...
Redeye comments on ChemoTech’s announcement that a clinical study evaluating its TSE technology for ...
Redeye considers AAC’s Q4 report to be soft, with revenues below its revised full-year guidance, pri...
Redeye provides an update on Scandinavian ChemoTech following the Q4 2025 report.
* NOI +8.2% y-o-y, +4.0% vs ABGSCe, +0.9% vs cons. * Value changes of +0.
Redeye updates its estimates and valuation following Momentum Group’s Q4 2025 report.
Redeye briefly comments on Initiator Pharma’s announcement that the EPO has granted a European paten...
Redeye comments on SSH’s Q4 report, which was softer than expected following the January guidance re...
Redeye is optimistic after Medivir's Q4 report. The new programme in osteogenesis imperfecta holds s...
Redeye provides a research update following the Q4 report recently published by Isofol.
Redeye retains its positive view of Avensia despite lowering our Base Case and forecasts.
Upsales redovisade ökad nettoomsättning och EBIT i det fjärde kvartalet.
Redeye returns with an update following Elicera’s Q4 earnings release.
Redeye reviews SynAct Pharma's Q4 report. A new European study in respiratory insufficiency was init...
Redeye provides a research update following the Q4 report published by Cinclus earlier today.
Redeye comments on Avensia’s Q4 report, showing softer margins than expected.
Following Insplorion’s recent announcement to divest its core hydrogen business, reported Q4 figures...
Redeye provides an initial take following Senzime’s Q4 2025 report.
Click below to watch the full video with CEO Philip Siberg's presentation of the company's report.
